HER2-positive

You have access
A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results
JUNJI KAWADA, DAISUKE SAKAI, YUTAKA KIMURA, MOTOHIRO HIRAO, KAZUHIRO NISHIKAWA, NAOTOSHI SUGIMOTO, YOSHIO OKA, SHUNJI ENDO, YUTAKA ISOZAKI, JIN MATSUYAMA, RYOHEI KAWABATA, TOMONO KAWASE, KAZUMASA FUJITANI, YUKINORI KUROKAWA, HISATO KAWAKAMI, TOSHIO SHIMOKAWA, TAROH SATOH and Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)

Anticancer Research March 2025, 45 (3) 1077-1085; DOI: https://doi.org/10.21873/anticanres.17495
Open Access
Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet
MOTOKAZU SATO, QINGHONG HAN, RYOSUKE MORI, KOHEI MIZUTA, BYUNG MO KANG, SEI MORINAGA, NORITOSHI KOBAYASHI, YASUSHI ICHIKAWA, ATSUSHI NAKAJIMA and ROBERT M. HOFFMAN

Anticancer Research April 2024, 44 (4) 1499-1504; DOI: https://doi.org/10.21873/anticanres.16946
You have access
Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years
MAMI KIKUCHI, TAKAAKI FUJII, CHIKAKO HONDA, KEIKO TANABE, YUKO NAKAZAWA, MISATO OGINO, SAYAKA OBAYASHI and KEN SHIRABE

Anticancer Research January 2023, 43 (1) 217-221; DOI: https://doi.org/10.21873/anticanres.16152
You have access
Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
NAR BAHADUR KATUWAL, NAHEE PARK, KAMAL PANDEY, MIN SIL KANG, SA DEOK HONG, MITHUN GHOSH, SEUL-GI KIM, YOUNG BIN CHO, JIN HUR, SEUNG KI KIM and YONG WHA MOON

Anticancer Research January 2023, 43 (1) 85-95; DOI: https://doi.org/10.21873/anticanres.16137
You have access
Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells
HYE YOUNG CHOI, HYO JUNG LEE, KYOUNG MI MOON, DONG KYU MOON, SECHAN LEE, HYEWON PARK, JINPYO HONG, MI JUNG PARK, DONG KYUN WOO and JAE CHEAL YOO

Anticancer Research July 2022, 42 (7) 3445-3452; DOI: https://doi.org/10.21873/anticanres.15831
You have access
Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin^®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin)
MARCUS SCHMIDT, SHERKO KÜMMEL, ANTONIA RUF-DOERDELMANN, ANDREA DISTELRATH, JÜRGEN WACKER, SABINE SCHMATLOCH, SASKIA BUSCH-LILES and KERSTIN LÜDTKE-HECKENKAMP

Anticancer Research January 2021, 41 (1) 485-496; DOI: https://doi.org/10.21873/anticanres.14799
You have access
Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer
LARS CHRISTIAN HANKER, FRANK FÖRSTER, JAN SCHRÖDER, ANDREA GRAFE, THOMAS HITSCHOLD, TOBIAS HESSE, CLAUS RICHARD LATTRICH and ACHIM RODY

Anticancer Research July 2020, 40 (7) 3973-3981; DOI: https://doi.org/10.21873/anticanres.14390
You have access
A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer
ATHINA STRAVODIMOU and IOANNIS A. VOUTSADAKIS

Anticancer Research July 2019, 39 (7) 3295-3301; DOI: https://doi.org/10.21873/anticanres.13471
You have access
Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer
DIMITRA STEFANOU, STEFANIA KOKKALI, ELLI-SOPHIA TRIPODAKI, MARIA DRIZOU, ELPIDA MAGOU, DIMOSTHENIS ZYLIS, MARIA PREVEZANOU, MATTHAIOS KAPIRIS, DESPOINA NASI, ANNA NTOKOU, MARY DEDE and ALEXANDROS ARDAVANIS

Anticancer Research November 2018, 38 (11) 6565-6569; DOI: https://doi.org/10.21873/anticanres.13023
You have access
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
KOICHI SAKAGUCHI, KATSUHIKO NAKATSUKASA, HIROSHI KOYAMA, MAKOTO KATO, AKIRA SAKUYAMA, TAKAYUKI MATSUDA, NOBUYUKI TSUNODA, IKUYA FUJIWARA, MASAHIDE YAMAGUCHI, HIROKI TANAKA, KAZUYOSHI ONISHI, MIE ONISHI, YUJI YOSHINO, TAKASHI KIKUCHI and TETSUYA TAGUCHI

Anticancer Research July 2018, 38 (7) 4073-4081; DOI: https://doi.org/10.21873/anticanres.12697

Main menu

User menu

Search

HER2-positive

Pages